menu

Improving Adherence and Persistence With Durable Anti-VEGF Therapies for nAMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Improving Adherence and Persistence With Durable Anti-VEGF Therapies for nAMD

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    This case consult with Dr Do and Dr Kaiser will consider a treatment-experienced patient referred for a 2nd opinion with decreased vision and prior diagnosis of neovascular AMD (nAMD). Dr Do and Dr Kaiser will discuss the recently approved anti-vascular endothelial growth factor (VEGF) agents with greater durability and longer dosing intervals that can decrease treatment burden. These retina specialists will evaluate the treatment responses in this patient and discuss whether to modify dosing intervals or switch therapies. This case illustrates the burden of care for patients with neovascular AMD (nAMD), and shows how to use the more durable anti-VEGF therapies in clinical practice to reduce treatment burden.

  • Target Audience

    This activity is designed to meet the educational needs of retina specialists, ophthalmologists, and other eye care/healthcare professionals who treat patients withage-related macular degeneration (AMD). 

  • Provider(s)/Educational Partner(s)

    This activity is provided by the American Academy of Ophthalmology, with support from Paradigm Medical Communications, LLC. 

  • Supporter Acknowledgment

    This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. 

  • Learning Objectives

    Upon completion of this activity, participants should be able to:

    • Apply the latest clinical findings for new anti-VEGF therapies that can potentially reduce nAMD treatment burden
  • Accreditation and Credit Designation Statements

    CME for Physicians 
    The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
     

    Designation Statement   
    The American Academy of Ophthalmology designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

  • Instructions for Participation

    To receive a certificate of participation, participants must: 

    • Follow instructions to register or log in with your professional information and complete the preassessment 
    • View the online activity in its entirety 
    • Complete and submit the online postassessment and evaluation. You must answer 70% of the postassessment questions correctly to earn credit. You will have unlimited opportunities to successfully complete the postassessment 

    A certificate of participation will be available for download/printing immediately following your successful completion of the postassessment and evaluation. 
     
    For questions regarding CME credit, contact the American Academy of Ophthalmology at cme@aao.org. 

    There are no fees for participating in this activity. 

  • Scientific Integrity and Disclosure of Financial Interest

    The American Academy of Ophthalmology is committed to ensuring that all CME information is based on the application of research findings and the implementation of evidence-based medicine. It seeks to promote balance, objectivity, and absence of commercial bias in its content. All persons in a position to control the content of this activity must disclose any and all financial interests. The Academy has mechanisms in place to resolve all conflicts of interest prior to an educational activity being delivered to the learners. 

    In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The Academy requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months. 

    All relevant relationships are identified and mitigated according to the Academy’s policy prior to individuals assuming their roles, and are disclosed prior to learners’ engagement in the activity. The Academy is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

    The content of this activity was independentlyreviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated. 

    A full listing of financial disclosures can be found below. All relevant financial relationships have been mitigated. 

    Diana V. Do, MD  
    Consultant/Advisor: Apellis Pharmaceuticals, Inc; Belite Bio; Boehringer Ingelheim; GENENTECH; Iveric Bio; Kodiak Sciences Inc; Kriya Therapeutics; Lumithera; Regeneron Pharmaceuticals Inc. 
    Grant Support: Lumithera 

    Peter K. Kaiser, MD 
    Consultant/Advisor: Allegro Ophthalmics, LLC; Allergan, Inc.; Annexon; Applied Genetic Technologies Corp.; Aviceda; Bausch + Lomb; Bayer Healthcare Pharmaceuticals; Biogen MA, Inc.; Boehringer Ingelheim; Clearside Biomedical, Inc.; Coherus Biosciences; Eyevensys; Formycon; Galimedix Therapeutics, Inc.; Irenix Medical, Inc.; Iveric Bio; jCyte; Kala Pharmaceuticals, Inc.; Nanoscope; Novartis Pharmaceuticals; Ocular Therapeutix; Oculis; Ocuphire; OcuTerra; Oxurion; Regeneron Pharmaceuticals, Inc.; REGENXBIO; Stealth Biotherapeutics; THEA 
    Stock Options – Public or Private Corp: Allegro Ophtalmics, LLC; Ocular Therapeutics; Ocuphire 
    Lecture Fee/Speakers’ Bureau: Bayer Healthcare Pharmaceuticals; Blogen MA, Inc; Novartis Pharmaceuticals; Regeneron Pharmaceuticals, Inc 

    The American Academy of Ophthalmology and Paradigm staff members have no relevant financial relationships with ineligible companies to disclose. 

    Independent peer reviewer has no relevant financial relationships with ineligible companies to disclose. 

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. 

  • Disclaimer

    This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, the American Academy of Ophthalmology or Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses. 

    If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified. 

    As an ACCME-accredited provider, the American Academy of Ophthalmology must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by the American Academy of Ophthalmology. 

    © 2024 American Academy of Ophthalmology except where noted. Content may not be reproduced in whole or part without the express written permission of the American Academy of Ophthalmology. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    This case consult with Dr Do and Dr Kaiser will consider a treatment-experienced patient referred for a 2nd opinion with decreased vision and prior diagnosis of neovascular AMD (nAMD). Dr Do and Dr Kaiser will discuss the recently approved anti-vascular endothelial growth factor (VEGF) agents with greater durability and longer dosing intervals that can decrease treatment burden. These retina specialists will evaluate the treatment responses in this patient and discuss whether to modify dosing intervals or switch therapies. This case illustrates the burden of care for patients with neovascular AMD (nAMD), and shows how to use the more durable anti-VEGF therapies in clinical practice to reduce treatment burden.

  • Target Audience

    This activity is designed to meet the educational needs of retina specialists, ophthalmologists, and other eye care/healthcare professionals who treat patients withage-related macular degeneration (AMD). 

  • Provider(s)/Educational Partner(s)

    This activity is provided by the American Academy of Ophthalmology, with support from Paradigm Medical Communications, LLC. 

  • Supporter Acknowledgment

    This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. 

  • Learning Objectives

    Upon completion of this activity, participants should be able to:

    • Apply the latest clinical findings for new anti-VEGF therapies that can potentially reduce nAMD treatment burden
  • Accreditation and Credit Designation Statements

    CME for Physicians 
    The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
     

    Designation Statement   
    The American Academy of Ophthalmology designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

  • Instructions for Participation

    To receive a certificate of participation, participants must: 

    • Follow instructions to register or log in with your professional information and complete the preassessment 
    • View the online activity in its entirety 
    • Complete and submit the online postassessment and evaluation. You must answer 70% of the postassessment questions correctly to earn credit. You will have unlimited opportunities to successfully complete the postassessment 

    A certificate of participation will be available for download/printing immediately following your successful completion of the postassessment and evaluation. 
     
    For questions regarding CME credit, contact the American Academy of Ophthalmology at cme@aao.org. 

    There are no fees for participating in this activity. 

  • Scientific Integrity and Disclosure of Financial Interest

    The American Academy of Ophthalmology is committed to ensuring that all CME information is based on the application of research findings and the implementation of evidence-based medicine. It seeks to promote balance, objectivity, and absence of commercial bias in its content. All persons in a position to control the content of this activity must disclose any and all financial interests. The Academy has mechanisms in place to resolve all conflicts of interest prior to an educational activity being delivered to the learners. 

    In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The Academy requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months. 

    All relevant relationships are identified and mitigated according to the Academy’s policy prior to individuals assuming their roles, and are disclosed prior to learners’ engagement in the activity. The Academy is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

    The content of this activity was independentlyreviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated. 

    A full listing of financial disclosures can be found below. All relevant financial relationships have been mitigated. 

    Diana V. Do, MD  
    Consultant/Advisor: Apellis Pharmaceuticals, Inc; Belite Bio; Boehringer Ingelheim; GENENTECH; Iveric Bio; Kodiak Sciences Inc; Kriya Therapeutics; Lumithera; Regeneron Pharmaceuticals Inc. 
    Grant Support: Lumithera 

    Peter K. Kaiser, MD 
    Consultant/Advisor: Allegro Ophthalmics, LLC; Allergan, Inc.; Annexon; Applied Genetic Technologies Corp.; Aviceda; Bausch + Lomb; Bayer Healthcare Pharmaceuticals; Biogen MA, Inc.; Boehringer Ingelheim; Clearside Biomedical, Inc.; Coherus Biosciences; Eyevensys; Formycon; Galimedix Therapeutics, Inc.; Irenix Medical, Inc.; Iveric Bio; jCyte; Kala Pharmaceuticals, Inc.; Nanoscope; Novartis Pharmaceuticals; Ocular Therapeutix; Oculis; Ocuphire; OcuTerra; Oxurion; Regeneron Pharmaceuticals, Inc.; REGENXBIO; Stealth Biotherapeutics; THEA 
    Stock Options – Public or Private Corp: Allegro Ophtalmics, LLC; Ocular Therapeutics; Ocuphire 
    Lecture Fee/Speakers’ Bureau: Bayer Healthcare Pharmaceuticals; Blogen MA, Inc; Novartis Pharmaceuticals; Regeneron Pharmaceuticals, Inc 

    The American Academy of Ophthalmology and Paradigm staff members have no relevant financial relationships with ineligible companies to disclose. 

    Independent peer reviewer has no relevant financial relationships with ineligible companies to disclose. 

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. 

  • Disclaimer

    This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, the American Academy of Ophthalmology or Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses. 

    If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified. 

    As an ACCME-accredited provider, the American Academy of Ophthalmology must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by the American Academy of Ophthalmology. 

    © 2024 American Academy of Ophthalmology except where noted. Content may not be reproduced in whole or part without the express written permission of the American Academy of Ophthalmology. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule22 Jun 2024